Track Neurocrine Biosciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Neurocrine Biosciences, Inc. NBIX · Stock Open Neurocrine Biosciences, Inc. in new tab

167.40 USD
P/E
24.84
EPS
6.74
P/B
4.37
ROE
20.42
Beta
0.33
Target Price
208.11 USD
Neurocrine Biosciences, Inc. logo

Neurocrine Biosciences, Inc.

🧾 Earnings Recap – Q3 2026

Neurocrine’s shares rose 13.4% after earnings, with investors responding to record product sales above $1.1 billion and a raised full-year INGREZZA outlook. INGREZZA’s 17% year-over-year sales growth and continued double-digit volume growth expectations led the positive read-through, alongside record profitability.

  • Net product sales exceeded $1.1 billion, up more than 40% year over year; non-GAAP earnings were above $3 per share.
  • INGREZZA sales were $801 million, up 17%; the company raised 2026 guidance to $2.9 billion–$2.925 billion. Q3 included a $20 million customer-order timing benefit expected to reverse in Q4.
  • Management expects INGREZZA’s double-digit volume growth in 2027 to more than offset anticipated mid- to high-single-digit net pricing headwinds.
  • CRENESSITY generated $211 million in sales, with more than 15% of the estimated diagnosed classic CAH population prescribed the drug. VYKAT XR sales were $107 million, driven by new patient demand.
  • Neurocrine reported record operating profitability, about $800 million in cash, and $400 million in operating cash flow; Phase III readouts for osavampator and direclidine are anticipated in 2027.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 10, 2027
P/E24.84
EPS6.74
Book Value38.29
Price to Book4.37
Debt/Equity11.65
% Insiders1.558%
Growth
Revenue Growth0.41%
Earnings Growth-0.04%
Estimates
Forward P/E13.61
Forward EPS12.30
Target Mean Price208.11

DCF valuation

Model fair value for Neurocrine Biosciences, Inc. (NBIX)
Result
Sign in to run the valuation for NBIX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
28 analysts · consensus Strong buy · mean target 208.11 USD (low 150.00, high 253.00) · as of 14 Nov 2026
Low 150.00
Mean 208.11
High 253.00
Price 167.40
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Neurocrine Biosciences, Inc. Logo Neurocrine Biosciences, Inc. Analysis (NBIX)

United States Health Care Official Website Stock

Is Neurocrine Biosciences, Inc. a good investment? Neurocrine Biosciences, Inc. (NBIX) is currently trading at 167.40 USD. Market analysts have a consensus price target of 208.11 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 24.84. This valuation is generally in line with the broader market.

Earnings Schedule: Neurocrine Biosciences, Inc. is expected to release its next earnings report on Feb. 10, 2027. The market consensus estimate for Forward EPS is 12.30.

Investor FAQ

Does Neurocrine Biosciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Neurocrine Biosciences, Inc.?

Neurocrine Biosciences, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 10, 2027. The company currently has a trailing EPS of 6.74.

Company Profile

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Exchange Ticker
NMS (United States) NBIX
LSE (United Kingdom) 0K6R.L
FRA (Germany) NB3.F
SAO (Brazil) N1BI34.SA
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion